Lv3
290 积分 2023-08-10 加入
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
1个月前
已完结
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer
1个月前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
3个月前
已完结
Tumor microenvironment evaluation in lung cancer: Spatio-temporal dynamics and clinical implications
3个月前
已关闭
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
3个月前
已完结
Third generation vs first generation EGFR-TKIs in the first line treatment for EGFR-mutated locally advanced or metastatic non-small cell lung cancer: a meta-analysis based on randomized controlled trials
3个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
3个月前
已完结
Organoids for tissue repair and regeneration
5个月前
已完结
Prognostic Value of the Extent of Lymphadenectomy for Overall Survival Among Patients with Non-muscle Invasive Bladder Cancer, A Retrospective Cohort Study
1年前
已完结
皖公网安备34019202002308
